Homepage
Hornet Therapeutics is a biotech startup focused on developing treatments to address Epstein-Barr Virus (EBV) driven pathologies.

Hornet Therapeutics, a biotech, develops EBV-driven treatments with lead in-licensed IDO-1 inhibitor HTX-201 for first-year transplant recipients at PTLD risk.
hornet-tx.comCrawled Nov 3, 2026
Hornet Therapeutics is a biotech startup focused on developing treatments to address Epstein-Barr Virus (EBV) driven pathologies.
This page details the Hornet Therapeutics Cookie policy
This page contains the Hornet Therapeutics legal disclosures
This page details the Hornet Therapeutics Privacy Policy
Hornet Therapeutics unveils new research on Epstein-Barr Virus (EBV) treatments, targeting cancers and autoimmune diseases linked to the virus. The company secures funding from 4BIO Capital to advance its therapeutic development. EBV infects over 90% of the global population and is associated with conditions like Burkitt’s lymphoma and multiple sclerosis.
Hornet Therapeutics secures seed funding from **4BIO Capital** to advance treatments for **EBV-driven diseases**. The London-based biotech company exits stealth mode with the capital to support early-stage research and development.
Hornet Therapeutics is advancing its IDO1 blocker **HTX-201** into clinical trials to treat **post-transplant lymphoproliferative disease**, an Epstein-Barr virus (EBV)-triggered condition. The company secures **$5 million in seed funding** to begin testing within **12–18 months**. HTX-201 targets immune pathways linked to EBV-driven complications in transplant patients.
Hornet Therapeutics unveils preclinical data in *Science* showing a potential drug candidate targeting Epstein-Barr virus (EBV)-associated diseases. The findings mark the first reported intervention specifically addressing EBV-driven conditions, including certain cancers and autoimmune disorders. The company exits stealth mode with this peer-reviewed validation of its research pipeline.
Hornet Therapeutics repurposes a shelved Kyowa Kirin drug candidate to target Epstein-Barr virus (EBV)-related diseases. The company focuses on preventing and treating conditions driven by EBV, leveraging the previously abandoned compound. Funding details remain unspecified in the report.